Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients. The sedation response of >100 moderately to severely affected COVID-19 ARDS was evaluated. The sedation level was measured at the bedside using the Richmond Agitation and Sedation Scale and ventilator synchrony. The evaluation was performed according to the static evaluation plan with respect to age, storage therapy and organ failure.
Description: Number of positioning therapys during treatment
Measure: Position therapy Time: Data collection is performed at the date of death from any cause or discharge up to 10 weeks.Description: Measurement is performed using the Richmond Agitation and Sedation Scale (RASS, range: -5[Unarousable] to +4 [Combative], normal condition=0 [Alert and calm])
Measure: Agitation and sedation level Time: 30 minutes after study enrolmentDescription: Change of sedation level using the Richmond Agitation and Sedation Scale (RASS, range: -5[Unarousable] to +4 [Combative], normal condition=0 [Alert and calm])
Measure: Agitation and sedation level Time: Change in average dosage within 8 hours.Description: Applied dosage of sufentanil (measured in µg/kg/h)
Measure: Application of opioid analgesic Time: 30 minutes after study enrolmentDescription: Applied dosage of sufentanil (measured in µg/kg/h)
Measure: Change of application of opioid analgesic Time: Change in average dosage within 8 hours.Description: Applied dosage of remifentanil (measured in µg/kg/min)
Measure: Application of opioid analgesic Time: 30 minutes after study enrolmentDescription: Applied dosage of remifentanil (measured in µg/kg/min)
Measure: Change of application of opioid analgesic Time: Change in average dosage within 8 hours.Description: Applied dosage of midazolam (measured in mg/kg/h)
Measure: Application of sedative Time: 30 minutes after study enrolmentDescription: Applied dosage of midazolam (measured in mg/kg/h)
Measure: Change in sedative dosage applied Time: Change in average dosage within 8 hours.Description: Applied dosage of propofol (measured in mg/kg/h)
Measure: Application of sedative Time: 30 minutes after study enrolmentDescription: Applied dosage of propofol (measured in mg/kg/h)
Measure: Change in sedative dosage applied Time: Change in average dosage within 8 hours.Description: Applied dosage of lormetazepam (measured in mg/kg/min)
Measure: Application of sedative Time: 30 minutes after study enrolmentDescription: Applied dosage of lormetazepam (measured in mg/kg/min)
Measure: Change in sedative dosage applied Time: Change in average dosage within 8 hours.Description: Applied dosage of clonidine (measured in µg/kg/h)
Measure: Application of sedative Time: 30 minutes after study enrolmentDescription: Applied dosage of clonidine (measured in µg/kg/h)
Measure: Change in sedative dosage applied Time: Change in average dosage within 8 hours.Description: Applied dosage of Dexmethomidine (measured in µg/kg/h)
Measure: Application of sedative Time: 30 minutes after study enrolmentDescription: Applied dosage of Dexmethomidine (measured in µg/kg/h)
Measure: Change in sedative dosage applied Time: Change in average dosage within 8 hours.Description: Applied dosage of esketamine (measured in mg/kg/h)
Measure: Application of sedative Time: 30 minutes after study enrolmentDescription: Applied dosage of esketamine (measured in mg/kg/h)
Measure: Change in sedative dosage applied Time: Change in average dosage within 8 hours.Description: Age (in years)
Measure: Patient Characteristics Time: The data is recorded at the time of enrolmentDescription: Height (in centimeters)
Measure: Patient Characteristics Time: The data is recorded at the time of enrolmentDescription: Weight (in kilograms)
Measure: Patient Characteristics Time: The data is recorded at the time of enrolmentDescription: The necessity and application of a renal replacement procedure is documented
Measure: Need for renal replacement therapy Time: Data collection is performed at the date of death from any cause or discharge up to 10 weeks.Description: The necessity and application of an extracorporeal oxygenation procedure (ECMO) is documented
Measure: Need for extracorporeal membrane oxygenation (vvECMO) Time: Data collection is performed at the date of death from any cause or discharge up to 10 weeks.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports